Merck KGaA at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Merck KGaA brings 12 presentations to ESGCT 2026 in Hamburg. Its contributions centre on producing and purifying AAV and lentiviral vectors at scale, including membrane chromatography capture and affinity steps. A second strand covers analytical methods that characterise vector proteins, particle quality and potency.
| Organization | ESGCT 2026 Attendance |
|---|---|
Merck KGaA Darmstadt, Germany | |
Science and technology group whose life science business supplies bioprocessing products, testing services and contract manufacturing for viral vectors. | Poster Wed Oct 28 1:30pm–3:30pm A scalable platform solution for AAV production from 3 L to 1000 L scale Poster Wed Oct 28 1:30pm–3:30pm Cation-Exchange Membrane Chromatography as a Non-Affinity Capture Strategy for Recombinant AAV Poster Wed Oct 28 1:30pm–3:30pm Characterization of viral proteins in adeno-associated virus for gene therapy using Capillary Electrophoresis (CE) Poster Wed Oct 28 1:30pm–3:30pm Evaluation of an upstream platform for efficient lentiviral vector manufacturing Poster Wed Oct 28 1:30pm–3:30pm Fast and reliable PAT-Raman model establishment for upstream monitoring of AAV production Poster Wed Oct 28 1:30pm–3:30pm From Bench to Pilot: Leveraging Platform Approaches for Seamless Scale-up of AAV Production Poster Wed Oct 28 1:30pm–3:30pm Structure-Activity-Relationship (SAR) study to characterize the cause of the thermo-induced potency reduction of adeno-associated virus for gene therapy Poster Wed Oct 28 1:30pm–3:30pm Viral vector characterization using field-flow fractionation coupled with multi-angle light scattering and dynamic light scattering (FFF-MALS-DLS) Manufacturing, CMC and access Poster Thu Oct 29 2:00pm–4:00pm Identifying and overcoming process and titer variability during HEK293 AAV production Poster Thu Oct 29 2:00pm–4:00pm Intensified AAV9 purification using novel, highly selective, caustic stable affinity capture Poster Thu Oct 29 2:00pm–4:00pm Optimization of baculovirus expression vector system to produce AAV8 in Sf9 derived insect cells Poster Thu Oct 29 2:00pm–4:00pm Using Next Generation Sequencing (NGS) as part of your potency assurance strategy for AAVs. |
Instantly find 20 buyers from Merck KGaA
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction